Full-Time

Digital Gbus Transformation and Value Realization lead

Confirmed live in the last 24 hours

Sanofi

Sanofi

10,001+ employees

Develops pharmaceuticals and life-saving vaccines

Biotechnology
Healthcare

Senior, Expert

Cambridge, MA, USA

Position requires onsite presence.

Category
Project Management
Strategy Development
Business & Strategy
Required Skills
Business Strategy
Data Analysis
Requirements
  • 10 years of professional experience especially with experience at a top strategic consulting firm
  • Solid industry background and understanding & process a strong business acumen (proven leadership experience in both commercial and digital roles with a focus on commercial)
  • Seasoned leader with outstanding communication and presentation skills.
  • Proven record of creating and implementing successful digital business strategies.
  • Very strong problem-solving skills and analytical capabilities
  • Very strong project management and execution skills
  • Ability to cultivate effective relationships, and to influence and collaborate internally and externally at all organizational levels.
  • Exceptional communication and influencing skills to effectively engage stakeholders at all levels.
  • Team player with great interpersonal skills, positive attitude, and confident demeanor.
  • A passion for innovation, problem-solving, and driving business transformation.
Responsibilities
  • Lead Quarterly Value Releases (QVR) process Cadenced process jointly with business including 90-day cycle value target setting and delivery and and provide holistic approach to product and value delivery, from end-to-end delivery of digital, analytics, tech components to revision of business processes to ensure easy product adoption and change management
  • Lead Transformation and Value Realization Office (TVRO) as X-functional and x-GBU body fostering value-driven decision making, prioritize resource allocation to new initiatives, resolve cross-GBU tradeoffs, as escalated by TVRO, Review value and product delivery targets and realization
  • Consolidates and validates blueprints across products
  • Synthetizes value targets and value realization
  • Escalates prioritization / x-GBU tradeoffs decisions to DAB
  • Acts as a spider in the web to coordinate technical feedback to POs on roadmap and blueprint, based on inputs collected from relevant SMEs
  • Validate individual product roadmap and quarterly blueprints submitted by POs and BOs
  • Validate allocation of resources for new products and suggest reallocation of resources across products (based on historical progresses, strategic priorities, expected returns of investments…)
  • Inform DAB of quarterly blueprint for individual products
  • Present relevant demos to DAB (jointly with relevant POs)
  • Escalate resolution of x-GBU tradeoffs to DAB
  • Own KPI framework, control tower, and change mgmt. framework

Sanofi provides healthcare solutions through its pharmaceutical and biotechnology products, focusing on treatments and vaccines for various medical conditions. The company conducts extensive research and development to create new therapies and improve existing ones, particularly in areas like immunology, oncology, and rare diseases. Sanofi's products include prescription medicines, over-the-counter items, and vaccines, which are distributed to patients, healthcare professionals, and governments. What sets Sanofi apart from its competitors is its strong emphasis on scientific innovation and strategic partnerships, allowing it to maintain a diverse pipeline of new products. The company's goal is to enhance health outcomes and improve the quality of life for people globally by delivering effective and safe healthcare solutions.

Company Stage

IPO

Total Funding

$2B

Headquarters

Paris, France

Founded

1973

Growth & Insights
Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Simplify Jobs

Simplify's Take

What believers are saying

  • AI-driven Muse tool can reduce clinical trial timelines and costs.
  • Dupixent's potential approval for chronic urticaria could expand Sanofi's market share.
  • Investment in SureChill aligns with sustainability trends and improves vaccine distribution.

What critics are saying

  • Muse's adoption may face privacy concerns and regulatory scrutiny.
  • ZT-01 trial may not yield expected returns for Sanofi's diabetes investment.

What makes Sanofi unique

  • Sanofi's collaboration with OpenAI on Muse enhances patient recruitment in clinical trials.
  • Dupixent's approval for eosinophilic esophagitis in children opens new pediatric markets.
  • Investment in Orano Med positions Sanofi in innovative radioligand cancer therapies.

Help us improve and share your feedback! Did you find this helpful?